Taxus Cardium Pharmaceuticals Stock Price - CRXM

Best deals to access real time data!
SMALL CAP BASIC
Monthly Subscription
for only
$29.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$59.99
SMALL CAP PRO
Monthly Subscription
for only
$43.59
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Taxus Cardium Pharmaceuticals Group, Inc. (PL) CRXM Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  +0.00364 +1.70% 0.21804 0.23 0.201 0.228099 0.2144 16:00:26
Bid Price Ask Price Spread Spread % News
0.09 0.23 0.14 60.87% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7 9,620 $ 0.2252 $ 2.17k 26.79k - - -
Last Trade Time Type Quantity Stock Price Currency
15:59:11 400 $0.22 USD

Taxus Cardium Pharmaceuticals Group, Inc. (PL) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
2833504.7592 12.78M $ -3.7M - -0.75 -
Short Interest Short % of Out Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
9.09k 0.07% $ - 0.00% - -

more financials information »

Taxus Cardium Pharmaceuticals Group, Inc. (PL) News


Historical CRXM Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.23780.2550.2010.000098373k31k-0.01976-8.31%
1 Month0.17990.2910.1430.0000983351k49k0.0381421.20%
3 Months0.170.2910.1060.00000351k29k0.0480428.26%
6 Months0.1680.36150.01050.00000351k22k0.0500429.79%
1 Year0.200.36150.01050.00000351k16k0.018049.02%
3 Years0.510.790.01050.00000394k19k-0.29196-57.25%
5 Years0.700.790.01050.00000394k19k-0.48196-68.85%

Taxus Cardium Pharmaceuticals Group, Inc. (PL) Description

Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen(R) topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx(R) is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.